ReShape Lifesciences, Inc. (HIND)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
HIND Chart
ReShape Lifesciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2 | $4.3 | $4.6 | $0.3 | 6.98% |
ReShape Lifesciences, Inc. (HIND) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ReShape Lifesciences, Inc. ever had a stock split?
ReShape Lifesciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Venkateswarlu Nelabhotla CEO | NASDAQ (NMS) Exchange | 92943X104 CUSIP |
| US Country | 18 Employees | - Last Dividend | 9 May 2025 Last Split | - IPO Date |
Overview
Vyome Holdings Inc. is a clinical-stage healthcare company committed to advancing therapeutic solutions for patients struggling with immuno-inflammatory and rare diseases. Established in 2017, the company is headquartered in Princeton, New Jersey, and operates within both the United States and global markets. Vyome's focus is directed towards innovative product development aimed at addressing unmet medical needs, thereby improving the quality of life for individuals affected by complex health conditions.
Products and Services
- Therapeutics for Immuno-Inflammatory Diseases
Vyome is engaged in the development of cutting-edge therapeutics specifically designed to target immuno-inflammatory diseases. These conditions often result in significant morbidity and require tailored treatment solutions. The company's research aims to address the root causes of these diseases, offering hope for improved outcomes for affected patients.
- Rare Disease Treatments
In addition to its work in immuno-inflammation, Vyome focuses on therapies for rare diseases, which are often overlooked in the pharmaceutical industry due to their limited market size. By leveraging advanced therapeutic modalities, Vyome seeks to bring to market effective treatment options that can make a substantial difference in the lives of patients suffering from these conditions.
- Clinical Development Programs
Vyome is actively involved in various clinical development programs aimed at advancing their therapeutic candidates through rigorous testing and validation. These programs are designed to evaluate the safety and efficacy of their products, ensuring that once brought to market, they meet the highest standards of patient care.
- Collaborations and Partnerships
The company understands the importance of collaboration in healthcare innovation. Vyome seeks partnerships with other biotech firms, academic institutions, and research organizations to enhance its product development pipeline and accelerate the delivery of transformative treatments to patients.
